以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 2月24日的资金流向数据方面，主力资金净流入1225.01万元，占总成交额6.64%，游资资金净流出 274.91万元，占总成交额1.49%，散户资金净流出950.1万元，占总成交额5.15%。 近5日资金流向一览见下表： 该股为中药，眼科，食品概念热股，当日中药概念上涨1.2%，眼科概念上涨1.11%，食品概念上涨 1.09%。 证券之星消息，天目药业2月24日涨停收盘，收盘价22.46元。该股于9点41分涨停，1次打开涨停，截止 收盘封单资金为1019.91万元，占其流通市值0.37%。 今日天目药业（600671）涨停的可能因素有：一是公司持续推进"精品中药+大健康"双轮战略，六味地 黄口服液、河车大造胶囊等独家中成药及铁皮石斛系列保健品形成产品矩阵；二是黄山天目产能提升及 技术改造项目（投资1亿元）预计2026年底一期投产，中药提取产能将大幅提升；三是珍珠明目滴眼液 正推进GMP符合性检查，临安制药中心等共40个药号已完成再注册，眼科产品线复产预期增强；四是 青岛国资背景强化， ...

在未来发展方面，公司黄山技改项目正稳步推进，一期主体已封顶，预计2026年底投产，届时将提升中 药提取和制剂产能。同时，公司产品复产计划（如珍珠明目滴眼液等）和渠道扩张（如全国营销体系搭 建）也在持续进行中。 以上内容基于公开资料整理，不构成投资建议。 经济观察网 基于最新公开信息，天目药业（600671）（600671）近期业绩改善明显，2025年前三季度 实现营业收入1.59亿元，同比增长27.48%，归母净利润1420.88万元，实现扭亏为盈。截至2026年2月11 日，公司股价报20.59元/股，总市值约25.07亿元，今年以来累计上涨18.95%。 公司项目推进 ...

（来源：中国医药报） 转自：中国医药报 □ 王树平 现代生活中，人们几乎每天都会使用电脑、手机等电子设备，长时间盯着各类电子屏幕容易出现视疲 劳。视疲劳不是一种独立的疾病，而是多种原因引起的一组症状，包括眼及眼眶周围疼痛、视物模糊、 眼睛干涩、流泪等，严重者还会出现头痛、恶心、眩晕等。 使用滴眼液是缓解眼部干涩、酸胀等症状的常用方法。与此同时，调整用眼习惯，从根源上减轻眼睛负 担，能有效降低视疲劳症状出现的频率。 常见产品 常用的滴眼液包括以下几种。 聚乙烯醇滴眼液是眼科常用药物，其主要作用机制是补充泪液，可用于预防或缓解眼睛干涩、异物感等 症状。需要注意的是，使用该滴眼液时可能出现眼部刺激和过敏反应。与之作用机制类似的，还有玻璃 酸钠滴眼液等。 萘敏维滴眼液是一种复方制剂，能缓解眼睛疲劳、结膜充血、眼睛发痒等症状，偶见瞳孔散大、充血加 重、刺激、眼部不适、视物模糊、轻度炎症等不良反应。需要注意的是，该滴眼液中的成分可能会导致 眼压快速升高，闭角型青光眼患者禁用。 珍珠明目滴眼液的主要成分是珍珠液和冰片，具有清热泻火、养肝明目的效果，可以改善眼部酸胀、干 涩等不适，常用于缓解视疲劳和治疗慢性结膜炎。过敏体质者 ...

Core Insights - The recent China-SCO (Belarus, Uzbekistan) International Medical and Pharmaceutical Industry Cooperation Conference held in Fangchenggang has led to multiple medical cooperation agreements among China, Belarus, and Uzbekistan [1][3] Group 1: Event Overview - The conference took place on November 26 in Fangchenggang, attended by numerous guests and pharmaceutical representatives from China, Belarus, and Uzbekistan [1] - A signing ceremony resulted in a memorandum of cooperation between the Fangchenggang International Medical Open Experimental Zone and the Belarus "Giant Stone" China-Belarus Industrial Park [3] Group 2: Key Agreements and Achievements - Strategic cooperation framework agreements were signed between the Fangchenggang International Medical Open Experimental Zone and Belarusian companies, focusing on traditional medicine development and personnel training [3] - The "Pearl Eye Drops," produced by Lezhu Pharmaceutical and registered in Belarus, marks a significant breakthrough for Chinese traditional medicine entering the SCO market [3] Group 3: Future Development and Collaboration - Fangchenggang aims to enhance its international medical cooperation with countries in the SCO, ASEAN, and Belt and Road Initiative, having established partnerships with various foreign industrial parks [5] - The Fangchenggang International Medical Open Experimental Zone is developing into a more open and inclusive platform, seeking to build international medical institutions and regional medical centers to provide healthcare services to SCO member states [6]

Core Viewpoint - Tianmu Pharmaceutical has shown significant improvement in financial performance for the first three quarters of 2025, with a revenue increase of 27.48% year-on-year and a net profit of 14.21 million yuan, indicating a turnaround from previous losses and ongoing operational enhancements [1][2]. Financial Performance - The company achieved a revenue of 159 million yuan in the first three quarters, reflecting a 27.48% increase compared to the same period last year, driven by the steady recovery of core business and deepening market channel development [2]. - The net profit attributable to shareholders reached 14.21 million yuan, a significant improvement from a loss of 3.70 million yuan in the previous year, indicating enhanced profitability and financial structure optimization [2]. - The equity attributable to shareholders increased by 27.12% year-to-date, reaching 666 million yuan, showcasing the positive impact of the state-owned capital entry in Qingdao [2]. Asset and Investment - As of the end of the reporting period, the total assets of Tianmu Pharmaceutical stood at 430 million yuan, remaining stable compared to the beginning of the year [3]. - The company's construction in progress increased nearly 9.6 times year-on-year to 13.25 million yuan, primarily due to increased investment in the Huangshan Tianmu technology transformation project, indicating accelerated capacity upgrades and technological improvements [3]. Strategic Initiatives - Tianmu Pharmaceutical is advancing the Huangshan Tianmu technology transformation project with a total investment expected to reach 100 million yuan, aiming for production by the end of 2026, which will significantly enhance the extraction capacity and production efficiency of traditional Chinese medicine [4]. - The management has emphasized a focus on three main sectors: traditional Chinese medicine manufacturing, pharmaceutical distribution, and health, while continuing product innovation and resumption of production [4]. - The company has received re-registration approval for 53 drugs, surpassing the total for the entire year of 2024, with successful progress on key products like the pearl eye drops and the launch of extended products in the Tiepi Fengdou series, contributing to long-term growth potential [4]. Industry Outlook - The industry is witnessing a gradual recovery supported by increasing government policy backing for traditional Chinese medicine, with Tianmu Pharmaceutical positioned to benefit from product restructuring and channel optimization [4]. - The company is transitioning from "recovery growth" to "steady quality improvement," laying a solid foundation for sustained growth through optimized industrial layout, strengthened marketing networks, and enhanced governance structures [4].

Group 1: 康恩贝 - The company aims to acquire potential large products that align with its strategic direction, with ongoing discussions for relevant targets [1] - The acquisition strategy considers strategic fit, revenue and profit potential, growth opportunities, and compatibility with existing treatment areas and marketing channels [1] - The company has strengthened its business development (BD) system, with a recently approved modified new drug for throat relief as an example of a more efficient and asset-light "acquisition" [1] Group 2: 甘李药业 - The company signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM for the production of insulin in Brazil [2] - The total amount of the supply framework agreement is expected to be no less than 3 billion RMB, with actual order amounts to be determined [2] - The agreement includes technology transfer for insulin and commitments for future procurement by FZ over the next 10 years [2] Group 3: 天目药业 - The company is focused on the inheritance and innovation of traditional Chinese medicine, accelerating the resumption of production for quality products like pearl eye drops [3] - It has made significant progress in drug re-registration, with 53 drugs receiving approval notifications since the beginning of 2025, surpassing the total for 2024 [3] - The company is leveraging existing product advantages to launch new products to meet diverse consumer needs [3] Group 4: 济民健康 - The company plans to enhance cooperation and increase investment in innovative drug research, aiming to establish Boao International Hospital as a high-level clinical research center [4] - The company holds a 51% stake in Boao International Hospital, with various stakeholders involved in the remaining shares [4] Group 5: 恒瑞医药 - The company signed a licensing agreement with Glenmark Specialty for its innovative drug SHR-A1811, with potential earnings exceeding 1.1 billion USD [5][6] - The drug targets HER2 and is designed to induce apoptosis in tumor cells, enhancing anti-tumor efficacy [5] - Glenmark Specialty will pay an upfront fee of 18 million USD and is eligible for milestone payments based on registration and sales [6] Group 6: 华熙生物 - The company’s strategic investment in Sanofi Pharmaceuticals is aimed at enhancing its presence in the biopharmaceutical sector [7] - The investment allows for collaboration in the development of small nucleic acid innovative drugs, creating synergies across its main business areas [7] - The company is exploring the role of hyaluronic acid and other substances in advanced medical research and applications [7]

Core Insights - The company is committed to the inheritance and innovation of traditional Chinese medicine, focusing on pharmaceutical manufacturing, distribution, and health sectors [1] - The company is accelerating the resumption of production for quality products like Pearl Eye Drops, guided by clinical value and efficacy [1] - The company has made significant progress in drug re-registration, with 53 drugs obtaining re-registration approval since the beginning of 2025, surpassing the total for the entire year of 2024 [1] - The company is leveraging existing product advantages to launch a series of products, including Iron Skin Feng Dou Tablets and Goji Berry Extract, to meet diverse consumer needs [1] - The company is planning capacity expansion based on market demand and strategic factors, with stable production operations [1] - A subsidiary is expected to invest 100 million yuan in capacity enhancement and technological transformation, significantly increasing the extraction capacity of traditional Chinese medicine [1] - The first phase of the project has been capped as of May 29, 2023, with production expected to commence by the end of 2026 [1]

Core Viewpoint - The company, Guofa Co., Ltd. (国发股份), has demonstrated strong confidence in its future development through significant share buybacks by its executives, signaling positive market sentiment and commitment to long-term investment [1][2]. Group 1: Share Buyback Activities - Chairman Jiang Ye completed a share buyback plan, acquiring a total of 4.8049 million shares for approximately 30.0166 million yuan [1]. - Jiang Ye's buyback activities included multiple transactions in August, with shares purchased at prices ranging from 6.19 yuan to 6.43 yuan per share [1]. - Another executive, Wu Peicheng, also completed a buyback plan, acquiring 381,500 shares for about 2.1393 million yuan, increasing his total holdings to 3.89 million shares [2]. Group 2: Financial Performance - For the first half of 2025, Guofa Co., Ltd. reported revenue of 154 million yuan, with a net loss of 5.8417 million yuan, showing improvement compared to previous periods [2]. - The company's pharmaceutical manufacturing segment generated revenue of 12.74 million yuan, while its medical distribution business contributed 95.37 million yuan [3]. Group 3: Business Segments and Developments - Guofa Co., Ltd. operates in various sectors, including pharmaceutical manufacturing, medical distribution, and judicial IVD (in vitro diagnostics) [2][3]. - The company has made significant personnel adjustments to enhance its governance structure, appointing new executives and independent directors [3]. - Guofa Co., Ltd. plans to raise up to 300 million yuan through a private placement to accelerate business innovation and upgrades [3]. Group 4: Strategic Initiatives - The company is exploring opportunities in the AI sector, as indicated by a recent visit to a leading cloud-native operating system company [4].

Company Overview - Beihai Guofa Chuanshan Biological Co., Ltd. is primarily engaged in pharmaceutical manufacturing and distribution, judicial IVD (in vitro diagnostics), and molecular medical imaging centers [3][11] - The company operates under various business models including direct sales, agency sales, and self-owned sales teams [5][6] Financial Performance - For the first half of 2025, the company reported a revenue of approximately 153.73 million yuan, a decrease of 13.02% compared to the same period last year [2] - The total profit for the period was a loss of approximately 4.58 million yuan, improving from a loss of 13.69 million yuan in the previous year [2] - The net profit attributable to shareholders was approximately -5.84 million yuan, compared to -16.11 million yuan in the same period last year [2] Industry Context - The pharmaceutical manufacturing industry in China saw a revenue of 1,227.52 billion yuan in the first half of 2025, a decline of 1.2% year-on-year [12] - The drug distribution industry experienced a significant slowdown, with a growth rate of only 0.6% in 2024, the lowest in 15 years [12] - The IVD market is expected to remain stable, with a projected market size of less than 120 billion yuan in 2024, indicating limited growth potential [13] Business Segments - The pharmaceutical manufacturing segment includes products such as eye drops, granules, and traditional Chinese medicine, with a focus on quality control and compliance with GMP standards [3][11] - The judicial IVD segment, operated by the subsidiary Gaoshen Biological, focuses on DNA testing equipment and services, utilizing a direct sales model primarily targeting public security units [5][6] - The molecular medical imaging center, managed by Beijing Xiangya, collaborates with medical institutions to provide imaging services and sells medical devices [11] Market Trends - The pharmaceutical industry is characterized by cyclical, regional, and seasonal demand patterns, with a relatively stable long-term outlook despite short-term fluctuations [11] - The IVD industry is witnessing a shift towards automation and intelligent detection technologies, driven by advancements in AI and big data [13][14]

Performance Meeting Overview - The company held its 2024 annual performance meeting on June 5, 2025, via an online interactive format at the Shanghai Stock Exchange [1] - Key executives including the Secretary of the Board, CFO, and an independent director participated in the meeting to address investor inquiries [1] Product Registration and Development - As of now, the company has completed re-registration for 29 drug numbers at its Lin'an Pharmaceutical Center, with 11 drug numbers at Huangshan Tianmu and Huangshan Mint also completed [2] - The company is working on small-scale trials and commissioned processing for some re-registered drug numbers to enhance its product diversity [2] Key Product Updates - The company's flagship product, Pearl Eye Drops, is undergoing preparations for GMP compliance checks, but the timeline for resuming normal production and sales remains uncertain [2] - The company has launched White Flower Snake Grass Water in collaboration with East China Grape Brewing Co., achieving sales revenue of 342.32 million yuan in 2024 [2] Health Product Strategy - The company is focused on a dual strategy of "premium traditional Chinese medicine + health products," aiming to expand its health product offerings [3] - New products such as Iron Skin Fengtou tablets, soft capsules, and extracts have been added to the existing product line [3] Collaborations and Market Expansion - The company has established a subsidiary for research and development in traditional Chinese medicine and health products, collaborating with renowned TCM teams [3] - Partnerships with Qingdao University aim to innovate TCM applications in health foods and functional products [3] E-commerce Initiatives - The company launched its flagship store on Tmall in May 2025, facilitating online sales of its Iron Skin Fengtou product line [4] - The company plans to leverage internet channels to enhance product promotion and expand market share [4] Mergers and Acquisitions - The company has adopted a cautious yet open approach to mergers and acquisitions, having acquired 51% stakes in Qingdao Simulation Medical Technology Co., Ltd. and Qingdao Tianmu Mountain Medical Technology Co., Ltd. in 2024 [5] - These acquisitions are expected to improve asset quality and enhance the company's operational capabilities [5]